Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$841 Mln
P/E Ratio
4.53
P/B Ratio
0.79
Industry P/E
9.84
Debt to Equity
0
ROE
0.19 %
ROCE
--
Div. Yield
14.25 %
Book Value
20.33
EPS
6.13
CFO
$-141.08 Mln
EBITDA
$611.16 Mln
Net Profit
$565.84 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Tekla Healthcare Investors (HQH)
| -0.31 | -4.99 | -9.96 | -0.81 | -9.08 | -4.84 | -7.91 |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Tekla Healthcare Investors (HQH)
| -3.11 | -7.94 | -24.24 | -0.29 | 14.13 | 16.32 | -20.30 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 14.31 | 1,499.33 | 7.82 | 10.88 | |
| 6.28 | 1,719.50 | 9.06 | 1.87 | |
| 20.17 | 5,648.93 | 9.65 | 8.69 | |
| 29.47 | 1,548.15 | 4.75 | 17.57 |
Abrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the... biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. Abrdn Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States. Read more
Portfolio Manager
Dr. Daniel R. Omstead M.S, Ph.D.
Portfolio Manager
Dr. Daniel R. Omstead M.S, Ph.D.
Headquarters
Philadelphia, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Tekla Healthcare Investors (HQH) stood at $ 1,062 Mln as on 31-Dec-24
The share price of Tekla Healthcare Investors (HQH) is $16.00 (NYSE) as of 25-Apr-2025 16:10 EDT. Tekla Healthcare Investors (HQH) has given a return of -9.08% in the last 3 years.
Tekla Healthcare Investors (HQH) has a market capitalisation of $ 841 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Tekla Healthcare Investors (HQH) is 0.79 times as on 25-Apr-2025, a 7% discount to its peers’ median range of 0.85 times.
The P/E ratio of Tekla Healthcare Investors (HQH) is 4.53 times as on 25-Apr-2025, a 54% discount to its peers’ median range of 9.84 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Tekla Healthcare Investors (HQH) and enter the required number of quantities and click on buy to purchase the shares of Tekla Healthcare Investors (HQH).
Abrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. Abrdn Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.
The CEO & director of Dr. Daniel R. Omstead M.S, Ph.D.. is Tekla Healthcare Investors (HQH), and CFO & Sr. VP is Dr. Daniel R. Omstead M.S, Ph.D..
There is no promoter pledging in Tekla Healthcare Investors (HQH).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
552
|
|
|
172
|
|
|
151
|
|
|
146
|
| Tekla Healthcare Investors (HQH) | Ratios |
|---|---|
|
Return on equity(%)
|
30.96
|
|
Operating margin(%)
|
527.81
|
|
Net Margin(%)
|
1694.62
|
|
Dividend yield(%)
|
14.25
|
No, TTM profit after tax of Tekla Healthcare Investors (HQH) was $0 Mln.
$-0.13
(
